Oregon Clinical and Translational Research Institute will be holding an informational Q&A session for the Biomedical Innovation Program Award, which is aimed at investigators who are thinking about submitting a letter of intent (due Sept. 9).
Tuesday, Aug. 11
11 a.m. to 12 p.m.
Mackenzie Hall, room 3198
David Ellison, M.D., professor of medicine and associate director of OCTRI, will present. A light lunch will be provided.
The focus of OCTRI’s Biomedical Innovation Program (BIP) is bench-to-bedside device, diagnostic, and software development. Formed in partnership with Technology Transfer and Business Development (TTBD) in 2012, the BIP has funded a total of 12 projects, led by a diverse group of principal investigators, including clinicians, scientists, and bioengineers. Several of these projects have achieved proof of concept as a result of BIP funding and are being actively marketed by TTBD for licensing agreements with biomedical corporations. Others have formed the basis for start-up companies. The BIP’s objective is to improve human health by moving innovative technologies from academia to the marketplace.
The current RFA can be viewed and download here.
Biomedical Innovation Program highlights
- Up to $40,000 in grant funding
- Project management
- Mentoring from OHSU faculty and staff, regional business partners, BIP review committee members
Questions? Please contact Jonathan Jubera at email@example.com
For more information about OCTRI awards and the Biomedical Information Program, please visit the OCTRI Funding Opportunities website.